T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-12-31: Form 8-K; Period of report 2014-12-29; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 2.03.
- 2014-10-17: Form 8-K; Period of report 2014-10-10; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2014-09-23: Form 8-K; Period of report 2014-09-22; Description 8.01 Other Events; Details 8.01.
- 2014-08-12: Form 8-K; Period of report 2014-08-12; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-12-31 | 8-K | 2014-12-29 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 2.03 On December 29, 2014, T2 Biosystems, Inc., a Delaware corporation (the “Company”), drew an aggregate of $10.0 million pursuant to tranche A of its Loan and Security Agreement (the “Loan Agreement”) with Solar Capital Ltd., as collateral agent and lender, and Comerica Bank, as lender (together, the “Lenders”), dated July 11, 2014, which resulted in net proceeds to the Company of approximately $9.99 million. | a14-26900_18k.htm |
| 2014-10-17 | 8-K | 2014-10-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a14-22629_18k.htm |
| 2014-09-23 | 8-K | 2014-09-22 | 8.01 Other Events | 8.01 On September 22, 2014, T2 Biosystems, Inc. issued a press release announcing that it received market authorization from the U.S. Food and Drug Administration for its first two products, the T2Candida® test panel and the T2Dx® instrument for the direct detection of Candida species in whole blood specimens from patients with symptoms of, or medical conditions predisposing the patient to, invasive fungal infections.. | a14-21308_18k.htm |
| 2014-08-12 | 8-K | 2014-08-12 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On August 12, 2014, T2 Biosystems, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock. | a14-18838_18k.htm |